

The Danish Cancer Society allocates DKK 6.5 million for research into optimal cancer treatment for older adults

In 2023, more than two out of three of all new cancer cases affected older adults. As the incidence of cancer increases with age, it is expected that even more people will be affected by cancer in the future, simply because there are more older adults in Denmark. In the coming years, the healthcare system will, therefore, diagnose, treat, and care for an increasing number of older adults with cancer.

Unique risk factors are primarily linked to the older age group, who often suffer from multiple diseases and the resulting polypharmacy and affected general conditions. In addition, there is poor nutritional status, a need for social and psychological support, and affected functional status.

Knowledge in the field is needed to develop, target, and provide the best treatment options for this group. Among other things, there is a lack of data on the effects and side effects of cancer treatment among older adults, partly because relatively few older people participate in randomised clinical trials.

The Danish Cancer Society wants to support efforts that focus on the treatment of older adults with cancer concerning research within

- Treatment of older cancer patients, including patients with multiple diseases
- Side effects
- Treatment tolerance
- Treatment effect and parameters thereof
- Inclusion of older patients in clinical trials
- Uncovering opportunities for individual adaptation of cancer treatment based on biological and clinical characteristics
- How treatment preferences and individual circumstances are identified and integrated into shared decision-making with older patients with cancer
- Knowledge of the cancer patient process, efforts and coordination across specialties and sectors for the elderly cancer patient

Assessment

The applications will be assessed by 7 members from the Cancer Society's Scientific Committee – Biology & Clinical (KBVU-BK), 3 members from the Cancer Society's Scientific Committee – Human & Society (KBVU-MS) and two patient representatives. The assessment process is expected to be completed by the end of September 2024.

The Committee will e.g., focus on the project's quality, originality, and feasibility, among other things. It is a requirement that the results of the funded projects will be published in relevant scientific and professional journals.

Results of development and intervention projects, etc., are expected to be disseminated nationally and, if possible, internationally in relevant professional environments.

Practical information

The applicant must meet the requirements defined in the Danish Cancer Society's Ethical Guidelines.

Funding is subject to sufficient available Knæk Cancer 2024 finances. The organisation of the Knæk Cancer campaign is in week 43 in October.

The Danish Cancer Society's usual funding and accounting conditions will apply in case of funding. The conditions are available on our website - please see below.

Deadline

Thursday, 20 June 2024 at 15:00

The signature page must be signed and sent by e-mail to forskningsbevilling@cancer.dk

Application form

The application must be completed according to the "Funding possibilities and guidelines" via the electronic application form on our website www.cancer.dk/kc-midler.

For questions related to the application form, please contact funding coordinator Anne Mette Bak at amb@cancer.dk or 3525 7257.

The Danish Cancer Society
Funding & follow-up

